Spiramycin


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Toxoplasmosis
Adult: 6-9 million units/day in 2-3 divided doses, increased to 15 million units/day, given in divided doses for severe infections.
Child: and neonates: Chemoprophylaxis of congenital toxoplasmosis: 50 mg/kg bid.

Oral
Cryptosporidiosis
Adult: 6-9 million units/day in 2-3 divided doses, increased to 15 million units/day, given in divided doses for severe infections.
Child: and neonates: Chemoprophylaxis of congenital toxoplasmosis: 50 mg/kg bid.

Oral
Susceptible infections
Adult: 6-9 million units/day in 2-3 divided doses, increased to 15 million units/day, given in divided doses for severe infections.
Child: and neonates: Chemoprophylaxis of congenital toxoplasmosis: 50 mg/kg bid.

Oral
Protozoal infections
Adult: 6-9 million units/day in 2-3 divided doses, increased to 15 million units/day, given in divided doses for severe infections.
Child: and neonates: Chemoprophylaxis of congenital toxoplasmosis: 50 mg/kg bid.

Intravenous
Toxoplasmosis
Adult: 1.5 million units by slow infusion every 8 hr, may double the dose in severe infections.

Intravenous
Protozoal infections
Adult: 1.5 million units by slow infusion every 8 hr, may double the dose in severe infections.

Intravenous
Susceptible infections
Adult: 1.5 million units by slow infusion every 8 hr, may double the dose in severe infections.

Intravenous
Cryptosporidiosis
Adult: 1.5 million units by slow infusion every 8 hr, may double the dose in severe infections.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity.
Special Precautions
Hepatic impairment; pregnancy and lactation. Monitor liver function. History of arrhythmias or predisposition to QT interval prolongation.
Adverse Reactions
Nausea, vomiting, abdominal pain, diarrhoea; urticaria, pruritus, macular rashes. Transient paraesthesia may occur.
Potentially Fatal: Pseudomembranous colitis; anaphylaxis; neuromuscular blockade; ventricular arrhythmias, prolongation of QT interval.
Drug Interactions
Decreases carbidopa absorption and levodopa concentrations. Increased risk of ventricular arrhythmias when used with astemizole, cisapride and terfenadine. Risk of acute dystonia when used with fluphenazine.
Action
Spiramycin is a macrolide antibacterial that inhibits protein synthesis by irreversibly binding to the 50S subunit of the ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
Absorption: Incompletely absorbed from the GI tract (oral); peak plasma concentrations after 1.5-3 hr.
Distribution: Widely distributed into tissues, enters breast milk. Protein binding: 10-25%.
Metabolism: Metabolised hepatically to active metabolites.
Excretion: Via bile (as metabolites), via urine (10%); 5-8 hr (elimination half-life).
CIMS Class
Macrolides
ATC Classification
J01FA02 - spiramycin ; Belongs to the class of macrolides. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on spiramycin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in